Drug Profile
Research programme: pancratistatin derivatives - Pierre Fabre
Alternative Names: F 98604Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Pierre Fabre
- Class
- Mechanism of Action DNA synthesis inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France
- 21 Apr 2010 Preclinical trials in Cancer in France (unspecified route)